Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension

Journal of Hypertension

Volumn 31, Issue 11, 2013, Pages 2290-2299

  Chaykovska, Lyubov ^a,b   Alter, Markus L ^a   Von Websky, Karoline ^a,c   Hohmann, Margarete ^a   Tsuprykov, Oleg ^a,c   Reichetzeder, Christoph ^a,c   Kutil, Barbara ^a   Kraft, Robin ^a   Klein, Thomas ^d   Hocher, Berthold ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF POTSDAM   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

2k1c renovascular hypertension; blood pressure; DPP4 inhibition; linagliptin; oxidative stress

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; COLLAGEN TYPE 1; CYSTATIN C; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TELMISARTAN;

ANIMAL; BLOOD; BLOOD PRESSURE; CARDIOMEGALY; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; FIBROSIS; HEART; HYPERTENSION, RENOVASCULAR; KIDNEY; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; RANDOMIZATION; RAT; STENOSIS, OCCLUSION AND OBSTRUCTION; SURGICAL EQUIPMENT; WISTAR RAT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOMEGALY; COLLAGEN TYPE I; CONSTRICTION, PATHOLOGIC; CYSTATIN C; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FIBROSIS; HEART; HYPERTENSION, RENOVASCULAR; KIDNEY; LINAGLIPTIN; LIPOPROTEINS, LDL; MALE; OXIDATIVE STRESS; PURINES; QUINAZOLINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SURGICAL INSTRUMENTS;

EID: 84885662277     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283649b4d     Document Type: Article

References (53)

1. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors -from preclinical development to clinical research. Kidney Blood Press Res 2012; 36:65-84.
2. Reynolds K, Wildman RP. Update on the metabolic syndrome: hypertension. Curr Hypertens Rep 2009; 11:150-155.
3. Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis 2011; 18:28-41.
4. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press Suppl 2001; 1:6-11.
5. Kosugi T, Heinig M, Nakayama T, Matsuo S, Nakagawa T. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am J Pathol 2010; 176:619-629.
6. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012; 60:833-841.
7. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010;1-11.
8. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 2008; 35:29-34.
9. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensinconverting enzyme inhibition in humans. Hypertension 2010; 56:728-733.
10. Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 2011; 6:e27861.
11. Torok J. Participation of nitric oxide in different models of experimental hypertension. Physiol Res 2008; 57:813-825.
12. Vávrová L, Kodydková J, Zeman M, Dušejovská M, Macášek J, Staňková B, et al. Altered activities of antioxidant enzymes in patients with metabolic syndrome. Obes Facts 2013; 6:39-47.
13. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 2003; 93:802-805.
14. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, et al. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 2006; 47:238-244.
15. Chaykovska L, Tsuprykov O, Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab 2011; 57:455-467.
16. Tanaka R, Shimizu M. The relationship between reactive oxygen species and cardiac fibrosis in the dahl salt-sensitive rat under ACEI administration. Vet Med Int 2012;1-6.
17. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 2011; 57:314-322.
18. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol 2003; 91 (10A): 28G-34G.
19. Fiordaliso F, Cuccovillo I, Bianchi R, Bai A, Doni M, Salio M, et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 2006; 79:121-129.
20. Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, Ma M, et al. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci 2011; 7:1077-1092.
21. Maejima Y,Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J, Isobe M. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 2011; 91:932-944.
22. Onishi K, Dohi K, Koji T, Funabiki K, Kitamura T, Imanaka-Yoshida K, et al. Candesartan prevents myocardial fibrosis during progression of congestive heart failure. J Cardiovasc Pharmacol 2004; 43:860-867.
23. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59:347-379.
24. Hocher B, George I, Diekmann F, Zart R, Rebstock J, Schwarz A, et al. ETA receptor blockade induces fibrosis of the clipped kidney in twokidney-one-clip renovascular hypertensive rats. J Hypertens 2000; 18:1807-1814.
25. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, et al. Lack of endothelial nitric oxide synthase promotes endothelininduced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol 2007; 18:730-740.
26. Amiri F, Garcia R. Renal angiotensin II receptor regulation in twokidney, one clip hypertensive rats: effect of ACE inhibition. Hypertension 1997; 30 (3 Pt 1):337-344.
27. Michel JB, Dussaule JC, Choudat L, Auzan C, Nochy D, Corvol P, Menard J. Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats. Kidney Int 1986; 29:1011-1020.
28. Hall JE, Guyton AC, Smith MJ Jr, Coleman TG. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol 1980; 239:F271-F280.
29. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69:105-113.
30. Jackson EK, Zhang M, Liu W, Mi Z. Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 2007; 323:431-437.
31. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005; 108:277-292.
32. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensinconverting enzyme inhibition in humans. Hypertension 2010; 56:728-733.
33. Tofovic DS, Bilan VP, Jackson EK. Sitagliptin augments angiotensin IIinduced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol 2010; 37:689-691.
34. Haefliger JA, Waeber B, Grouzmann E, Braissant O, Nussberger J, Nicod P, Waeber G. Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats. Regul Pept 1999; 82:35-43.
35. Oellerich WF, Malik KU. Neuropeptide Y modulates the vascular response to periarterial nerve stimulation primarily by a postjunctional action in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993; 266:1321-1329.
36. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2009; 118:31-41.
37. Cheng Q, Law PK, de Gasparo M, Leung PS. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl) ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]- 4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 2008; 327:683-691.
38. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 327:119-130.
39. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a nondialysable uremic toxin, indoxyl sulfate. PLoS One 2012; 7:e41281.
40. Müller P, Kazakov A, Semenov A, Jagoda P, Friedrich EB, Böhm M, Laufs U. Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs. J Cardiovasc Pharmacol Ther 2013; 18:87-93.
41. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122:16-27.
42. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A prespecified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11:1-10.
43. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013.
44. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 2011; 162:620-626; e1.
45. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53:654-662.
46. de Champlain J, Wu R, Girouard H, Karas M, EL Midaoui A, Laplante MA, Wu L. Oxidative stress in hypertension. Clin Exp Hypertens 2004; 26:593-601.
47. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res 2012; 94:316-323.
48. Connelly K, Zhang Y, Advani A, Advani S, Thai K, Yuen D, Gilbert R. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodelling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther 2012;1755-5922.
49. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation 2008; 117:2340-2350.
50. Simic DV, Mimic-Oka J, Pljesa-Ercegovac M, Savic-Radojevic A, Opacic M, Matic D, et al. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens 2006; 20:149-155.
51. Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011; 51:906-918.
52. Matsui T, Nishino Y, Takeuchi M, Yamagishi S. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011; 63:383-388.
53. Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012; 96:140-149.